Table 2.
Comparison of primary care treated patients (n=327) compared with patients treated in secondary care (n=551)
| Primary care | Secondary care | P values | |
| Age (median and IQR) | 48 (38–56) | 54 (46–59) | <0.0001 |
| Sex—male (%) | 66 | 66 | NS |
| Genotype (%) | |||
| 1a | 46 | 41 | NS |
| 1b | 10 | 10 | NS |
| 2 | 2 | 7 | <0.05 |
| 3 | 40 | 40 | NS |
| Other | 2 | 2 | NS |
| Treatment history (%) | |||
| Naïve | 92 | 75 | <0.05 |
| TE no PI | 6 | 18 | <0.05 |
| TE and PI | 1 | 6 | NS |
| Prior DAA failure | 1 | 1 | NS |
| Duration of treatment, weeks (%) | |||
| 8 | 26 | 11 | <0.001 |
| 12 | 72 | 66 | NS |
| 24 | 2 | 23 | <0.05 |
| Fibrosis stage (%) | |||
| F0 | 22 | 16 | <0.05 |
| F1 | 40 | 23 | <0.05 |
| F2 | 18 | 15 | NS |
| F3 | 10 | 11 | NS |
| F4 | 10 | 35 | <0.05 |
DAA, direct- acting antiviral agent; NS, not significant; PI, protease inhibitor; TE, treatment experienced.